McKesson saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 67 to 73.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves. See if McKesson can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
McKesson is trying to complete a cup with handle with a 632.59 buy point. See if the stock can clear the breakout price in heavy volume.
The company posted 4% earnings growth in its most recent report. Revenue rose 18%.
The company earns the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
